Israel Englander’s GT Biopharma GTBP Stock Holding History

Israel Englander’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,198	Closed	-$16.8K	–	6364
2023 Q4	$16.8K	Sell	2,198 -736	-25%	-$5.38K	﹤0.01%	5662
2023 Q3	$21.2K	Sell	2,934 -4,895	-63%	-$40.5K	﹤0.01%	5639
2023 Q2	$73.3K	Buy	7,829 +3,065	+64%	+$31.8K	﹤0.01%	5397
2023 Q1	$79K	Buy	4,764 +367	+8%	+$8.41K	﹤0.01%	5497
2022 Q4	$118K	Sell	4,397 -736	-14%	-$36.8K	﹤0.01%	5519
2022 Q3	$271K	Sell	5,133 -3,006	-37%	-$230K	﹤0.01%	5453
2022 Q2	$730K	Buy	+8,139	New	+$617K	﹤0.01%	4660
2021 Q4	–	Sell	-1,138	Closed	-$230K	–	7020
2021 Q3	$230K	Buy	+1,138	New	+$342K	﹤0.01%	6020
2021 Q2	–	Sell	-930	Closed	-$191K	–	6734
2021 Q1	$191K	Buy	+930	New	+$162K	﹤0.01%	5510

Other funds holding GTBP

Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Israel Englander's GTBP Position: Q1 2024 in Review

Israel Englander sold out of GT Biopharma (GTBP) in Q1 2024, closing a stake of 2,198 shares — an estimated $16.8K sold.

Israel Englander first reported a position in GTBP in Q1 2021 and held it in 9 quarters. The position peaked at $730K in Q2 2022. 17 funds tracked by Wall St. Rank hold GTBP as of Q1 2024.

Israel Englander reported no remaining GT Biopharma position as of Q1 2024 after selling out during the quarter.
Israel Englander sold 2,198 GT Biopharma shares in Q1 2024, an estimated $16.8K.
Israel Englander first reported a position in GT Biopharma in Q1 2021 and held it in 9 quarters.
Israel Englander's GT Biopharma position peaked at $730K in Q2 2022.
17 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2024.

Based on Millennium Management's 13F filing for Q1 2024, filed 15 May 2024.